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Reconstructed human epidermis (RHE) mimic normal human in vivo 
epidermis in terms of histology, distribution of differentiation mark-
ers and barrier functionality.1
A typical transcriptional profile and the activation of signalling 
pathways reminiscent of atopic dermatitis (AD) lesional skin can 
be obtained in RHE upon incubation with methyl- β- cyclodextrin 
(MβCD),2,3 a molecule that extracts cholesterol from plasma mem-
branes, thereby disrupting lipid microdomains. However, barrier func-
tion and morphology remain unaltered in those conditions, requiring 
further refinement of the model.
2 | QUESTION­ADDRESSED
Because of the crucial role played by Th2 immune response in 
AD, a mixture of interleukins linked to this Th2 response (IL- 4, 
IL- 13 and IL- 25) was used in addition to MβCD, in an attempt 
to induce most of the epidermal AD features in RHE. Ultimately, 
a valid RHE model of acute AD would allow studying the epidermal 
component of pathogenesis.
3 | EXPERIMENTAL­DESIGN
Reconstructed human epidermis was incubated for 2 hours with 
MβCD in order to induce cholesterol depletion (Fig. S1), then for 
48 hours with the interleukin mix and compared to control tissues, 
and to tissues incubated with either MβCD or interleukins.
4 | RESULTS
When allowed to recover in fresh culture medium after incubation 
with MβCD for 2 hours, RHE revealed no obvious histological 
alteration when compared with untreated RHE (Fig. 1a). Conversely, 
RHE treated with IL- 4, IL- 13 and IL- 25 for 48 hours displayed 
intercellular space widening similar to spongiosis (already reported 
for IL- 4 and IL- 13 4–6) and hypogranulosis, two histological hall-
marks of lesional AD skin (Fig. S2). These morphological alterations 
were enhanced when keratinocytes were challenged by MβCD 
before being incubated with the three interleukins (Fig. 1a).
Barrier function, weakened in AD, was studied using two assays: 
measurement of trans- epithelial electrical resistance (TEER) and 
assessment of permeability to the fluorescent dye lucifer yellow (LY) 
through the RHE. A significant decrease in TEER was observed in RHE 
incubated with the interleukins, and worsened upon membrane cho-
lesterol depletion (Fig. 1b). Accordingly, permeability of RHE towards 
LY was significantly increased after combined treatments, whereas 
cholesterol depletion alone or incubation with interleukins only was 
insufficient to elicit an effect (Fig. 1c).
Then, the expression of atopic dermatitis markers was investigated. 
Gene expression of filaggrin (FLG) and loricrin (LOR), epidermal differ-
entiation genes usually downregulated in lesional AD, was analysed 
through RT- qPCR (Fig. 2a). FLG and LOR exhibited reduced mRNA 
levels in RHE incubated with IL- 4, IL- 13 and IL- 25, as already reported 
in the literature regardless of the different concentrations and timings 
used.5 This decrease was exacerbated and became significant when 
keratinocytes were challenged by cholesterol depletion before incu-
bation with the interleukins. Simultaneously, relative expression levels 
of carbonic anhydrase II (CA2) and neural epidermal growth factor- like 
2 (NELL2), two genes upregulated in AD,7 were significantly enhanced 
in RHE in response to incubation with interleukins (Fig. 2a).
Immunohistological analysis confirmed decreased expression of 
LOR and increased expression of CA2 in AD lesions (Fig. S3a). Similar 
changes were observed in RHE treated with interleukins and became 
even more evident in tissues previously treated with MβCD (Fig. S3b).
Expression levels for hyaluronan synthase 3 (HAS3) were found 
elevated in RHE exposed to interleukins and further increased after 
combined treatments (Fig. 2a), in agreement with the upregulation 
observed in AD.4,8 Though, no significant changes were found with 
respect to HAS1 expression levels (data not shown), unlike data col-
lected from AD lesions.8
Fluorescent detection of hyaluronic acid (HA) revealed increased 
staining of intercellular spaces between keratinocytes in AD lesions 
(Fig. S4a). HA was also more strongly detected in RHE incubated with 
interleukins, particularly after previous challenging by MβCD (Fig. 
S4b). Accordingly, increased HA concentrations were measured in 
 culture medium of treated RHE (Fig. S4c).
Thymic stromal lymphopoïetin (TSLP) is a cytokine, upregulated in 
AD, which contributes to Th2 immune response activation, promotes 
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itch in skin and the “atopic march” in general.9 However, despite sig-
nificant induction in response to 2 hours of MβCD (Fig. S1c), mRNA 
expression levels for TSLP were no longer above baseline 48 hours later 
(Fig. 2a). However, in the meantime, over the 6 hours period following 
cholesterol depletion (Fig. 2b), data illustrate that interleukins and MβCD 
concur to significantly enhance TSLP expression in challenged RHE.
5 | CONCLUSIONS
This study illustrates that challenging RHE through cholesterol 
depletion, or by incubation with IL- 4, IL- 13 and IL- 25, results in 
multiple epidermal alterations. But interestingly, a combination of 
those two treatments has additive effects, allowing mimicking an 
AD- like epidermal phenotype in vitro in the absence of immune 
cells. Indeed, morphological alterations such as tissue spongiosis 
and hypogranulosis, alterations in mRNA expression levels and 
histological localizations of typical AD and differentiation markers, 
modulations of epidermal HA synthesis and epidermal barrier weak-
ening represent hallmarks of AD epidermis.
In vivo, such alterations become responsible for activation of the 
immune system because they promote penetration of pathogens or 
allergens, thereby creating some vicious circle likely responsible for AD 
lesions development (Fig. 2c).
Most probably, challenging of keratinocytes by MβCD models 
alterations in cell signalling through disorganization of specific lipid 
microdomains in this cell type.3 Interestingly, gene expression levels 
for IL- 13Rα2, IL- 13Rα1, IL- 4Rα and IL- 17RA (subunit of IL- 25 recep-
tor) were upregulated in keratinocytes incubated with MβCD.3 This 
F IGURE  1 Morphology and barrier efficiency in treated 
reconstructed human epidermis (RHE). (a) Histological sections 
of RHE treated for 2 hours with MβCD followed by 48 hours of 
recovery (MβCD 2 hours+recovery 48 hours) or treated for 48 hours 
with IL- 4, IL- 13 and IL- 25 (IL 48 hours), or a combination of both 
treatments (MβCD 2 hours+IL 48 hours), compared to non- treated 
RHE (Ctrl 48 hours). Images are representative of three independent 
cultures. Scale bar=50 μm. Analysis of barrier function, by (b) 
trans- epidermal electrical resistance (TEER) or (c) fluorescence 
quantification of lucifer yellow permeation in the culture medium, of 
RHE treated for 2 hours with MβCD (MβCD2 hours), followed or not 
by 48- hour incubation with interleukins 4, 13 and 25 (IL 48 hours). 
Data represent measurements performed on three independent 
cultures (error bars=SEM, one- way RM ANOVA and *P<.05, **P<.01)
F IGURE  2 Transcriptional regulation of atopic dermatitis markers 
in treated reconstructed human epidermis (RHE) and hypothetical 
simplified model for AD- like pathogenesis. (a) RT- qPCR analysis 
of the expression of filaggrin (FLG), loricrin (LOR), thymic stromal 
lymphopoietin (TSLP), carbonic anhydrase II (CA2), neural epidermal 
growth factor- like 2 (NELL2) and hyaluronan synthase 3 (HAS3) was 
performed on total RNA extracted from RHE treated with MβCD 
(MβCD2 hours) and/or interleukins 4, 13 and 25 (IL48 hours). Levels 
of mRNA expression in control conditions were arbitrarily fixed at 
1. Error bars represent 95% confidence intervals (n=3 independent 
cultures, one- way RM ANOVA, *P<.05, **P<.01, ***P<.001). (b) TSLP 
mRNA expression was quantified by RT- qPCR in RHE incubated for 
2 hours with MβCD, followed or not by incubation with IL- 4, IL- 13 
and IL- 25 for 2, 4 or 6 hours. Values are expressed relative to control 
condition (no MβCD+no IL). Error bars represent 95% confidence 
intervals (n=3 independent cultures, two- way RM ANOVA, *P<.05, 
**P<.01, ***P<.001). (d) Plasma membrane cholesterol depletion 
with MβCD in RHE challenges keratinocytes which in turn produce 
TSLP, a Th2 response- activating cytokine. Addition of Th2- related 
interleukins in the culture medium intends to mimic consequences 
of the activation of immune cells in vivo. Response of challenged 
RHE includes morphological alterations as well as weakening of the 
epidermal barrier. In vivo, activation of the immune system resulting 
from altered barrier function would maintain the vicious circle 
observed in AD
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indicates that cholesterol- containing lipid microdomains could regu-
late signalling through these receptors and could therefore explain the 
additive effects observed in this study.
In conclusion, this study confirms that membrane cholesterol 
depletion in keratinocytes concurs with Th2- related cytokines to elicit 
an AD- like phenotype. The present model could be used to study 
other features encountered in AD epidermis, but also evaluate com-
pounds intending to relieve, prevent AD lesions or restore keratino-
cyte functions.
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